Industry
Biotechnology
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Loading...
Open
46.76
Mkt cap
5.5B
Volume
1.1M
High
47.30
P/E Ratio
-15.84
52-wk high
50.78
Low
44.85
Div yield
N/A
52-wk low
5.15
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 11:06 am
Portfolio Pulse from Vandana Singh
September 24, 2024 | 6:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 10:45 am
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 1:20 pm
Portfolio Pulse from Benzinga Insights
September 16, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 5:01 pm
Portfolio Pulse from Vandana Singh
September 09, 2024 | 6:28 pm
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 4:08 pm
Portfolio Pulse from Benzinga Insights
August 28, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 12:28 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.